- Home
- SFL vs AKRO Comparison
SFL vs AKRO Comparison
Compare SFL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFL
- AKRO
- Stock Information
- Founded
- SFL 2003
- AKRO 2017
- Country
- SFL Bermuda
- AKRO United States
- Employees
- SFL N/A
- AKRO N/A
- Industry
- SFL Marine Transportation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- SFL Consumer Discretionary
- AKRO Health Care
- Exchange
- SFL Nasdaq
- AKRO Nasdaq
- Market Cap
- SFL 1.1B
- AKRO 3.9B
- IPO Year
- SFL N/A
- AKRO 2019
- Fundamental
- Price
- SFL $8.87
- AKRO $51.74
- Analyst Decision
- SFL Strong Buy
- AKRO Strong Buy
- Analyst Count
- SFL 1
- AKRO 6
- Target Price
- SFL $13.00
- AKRO $82.50
- AVG Volume (30 Days)
- SFL 1.3M
- AKRO 1.7M
- Earning Date
- SFL 08-13-2025
- AKRO 08-08-2025
- Dividend Yield
- SFL 12.08%
- AKRO N/A
- EPS Growth
- SFL N/A
- AKRO N/A
- EPS
- SFL 0.41
- AKRO N/A
- Revenue
- SFL $852,590,000.00
- AKRO N/A
- Revenue This Year
- SFL N/A
- AKRO N/A
- Revenue Next Year
- SFL $3.20
- AKRO N/A
- P/E Ratio
- SFL $22.03
- AKRO N/A
- Revenue Growth
- SFL 6.58
- AKRO N/A
- 52 Week Low
- SFL $6.78
- AKRO $21.34
- 52 Week High
- SFL $14.05
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- SFL 57.60
- AKRO 52.50
- Support Level
- SFL $8.21
- AKRO $50.13
- Resistance Level
- SFL $9.07
- AKRO $52.73
- Average True Range (ATR)
- SFL 0.22
- AKRO 2.09
- MACD
- SFL 0.03
- AKRO -0.76
- Stochastic Oscillator
- SFL 76.74
- AKRO 34.00
About SFL SFL Corporation Ltd
SFL Corp Ltd is an international ship-owning and chartering company. The company is engaged in transporting crude oil and oil products, dry bulk and containerized cargoes, freight of rolling cargo, and offshore drilling and related activities.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.